Blog
How it works
Services
Sign In
Homepage
Blog
How it works
Services
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
KRBP.US
id: 115, Created by Stan Vick Chase, Scout

Kiromic Biopharma Inc

The public offering closed on July 2, 2021, more than 30 days after the Company submitted the IND applications for its two immunotherapy product candidates.
Investors were assured that no clinical hold had been issued and clinical trials would commence.
In fact, the Company received communications from the FDA on June 16 and 17, 2021, stating that the FDA was placing the IND applications for its two candidates.
The Offering Documents failed to disclose this information, instead representing that clinical testing was expected to proceed in the third quarter of 2021.
As a result, those investors who purchased the company's shares at a price of $ 5 as part of a public offering, making a decision based on deliberately false information, have already lost about 90% of their investments.
Alleged Offence
Misleading Statements
Failure to Disclose
Malpractice
Negligence
Breach of Fiduciary duty
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
02 July 2021
Collecting participants…
Created by Stan Vick Chase, Scout

Kiromic Biopharma Inc

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency ...

    Ticker
    KRBP.US
    ISIN
    US4976341051
    CIK
    1792581
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    7707 Fannin, Houston, TX, United States, 77054